May S.K. Sutherland

SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

May S.K. Sutherland, Roland B. Walter, Scott C. Jeffrey et al. · Blood · 2013 · 386 citations

Pharmacy, Oncology, Pharmacology +13

Lysosomal Trafficking and Cysteine Protease Metabolism Confer Target-specific Cytotoxicity by Peptide-linked Anti-CD30-Auristatin Conjugates

May S.K. Sutherland, Russell J. Sanderson, Kristine A. Gordon et al. · Journal of Biological Chemistry · 2006 · 296 citations · Full text

Medicine, Oncology, Pharmacology +16

Sclerostin Inhibition of Wnt-3a-induced C3H10T1/2 Cell Differentiation Is Indirect and Mediated by Bone Morphogenetic Proteins

David G. Winkler, May S.K. Sutherland, Ethan W. Ojala et al. · Journal of Biological Chemistry · 2004 · 164 citations · Full text

Life Sciences, Developmental Biology, Bone Metabolism +16

IL-6 as a drug discovery target

Bernd Stein, May S.K. Sutherland · Drug Discovery Today · 1998 · 44 citations

Pharmacy, Immunology, Medicinal Chemistry +10

Age-dependent expression of osteoblastic phenotypic markers in normal human osteoblasts cultured long term in the presence of dexamethasone

May S.K. Sutherland, L.G. Rao, Syed A. Muzaffar et al. · Osteoporosis International · 1995 · 37 citations

Medicine, Orthopedic Surgery, Bone Metabolism +14